Carregant...
Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD
INTRODUCTION: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated safety and efficacy versus placebo in phase III trials in patients with anemia of chronic kidney disease (CKD) who were not on dialysis (NDD). METHODS: This was a phase III, active-control...
Guardat en:
| Publicat a: | Kidney Int Rep |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8258605/ https://ncbi.nlm.nih.gov/pubmed/34307976 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ekir.2021.04.003 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|